ArticleMMWR. Morbidity and mortality weekly report2024
Tuberculosis - United States, 2023.
Article in MMWR. Morbidity and mortality weekly report, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Systematic Review of Contact Investigation Costs for Tuberculosis, United States.Emerging infectious diseases · 2025Pooled it
- Role of dormancy survival regulator and resuscitation-promoting factors antigens in differentiating between active and latent tuberculosis: a systematic review and meta-analysis.BMC pulmonary medicine · 2024Pooled it
- Article
- Tuberculosis Risk in the Returning Traveler: Assessing Tuberculosis Test Conversion Among Routinely Tested Patients at an Asian American Health Center.Open forum infectious diseases · 2026Article
- AI Based Cough Analysis for Pulmonary Tuberculosis Triage and Diagnosis: A Technical Review.npj biomedical innovations · 2026Review
- Expanding the Frontiers of Tuberculosis Prevention: Moving from Targeted Preventive Therapy to Integrated Public Health Strategies.Tropical medicine and infectious disease · 2026Article
- Gemifloxacin resistance inMicrobiology spectrum · 2026Article
- Using the Health Belief Model To Assess the Impact of Latent Tuberculosis Infection Health Education Video Towards Screening Adoption in Non-US-Born Persons Living in California.Journal of immigrant and minority health · 2026Article
- Current perspective on infectious uveitis.Indian journal of ophthalmology · 2026Review
- Characteristics of Plausible Source Cases Responsible for Recent Mycobacterium tuberculosis Transmission, United States, 2018-2022.Emerging infectious diseases · 2026Article
- Preferences for treatment for latent tuberculosis infection in primary care among people in the United States at increased risk of tuberculosis: a pilot survey.medRxiv : the preprint server for health sciences · 2026Article
- U.S. Health department roles and challenges in conducting contact evaluation for tuberculosis aircraft contact investigations.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- Acidic pH Restricts Non-Tuberculous Mycobacteria Replication.Molecular microbiology · 2026Article
- Healthcare system strain and healthcare seeking behavior: the lingering impact of the COVID-19 pandemic on TB delayed diagnosis in Snohomish County, Washington.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- Hepatitis C and risk of tuberculosis amongst United States veterans: a national cohort study.Lancet regional health. Americas · 2026Article
- Identification and characterization of inhibitors of the tuberculosis phosphatase PstP.The Journal of biological chemistry · 2026Article
- Article
- Article
- Article
- Tuberculosis before and during COVID-19 Pandemic, United States, 2010-2023.Emerging infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After 27 years of declining U.S. tuberculosis (TB) case counts, the number of TB cases declined considerably in 2020, coinciding with the COVID-19 pandemic. For this analysis, TB case counts were obtained from the National TB Surveillance System. U.S. Census Bureau population estimates were used to calculate rates overall, by jurisdiction, birth origin, race and ethnicity, and age group. Since 2020, TB case counts and rates have increased each year. During 2023, a total of 9,615 TB cases were provisionally reported by the 50 U.S. states and the District of Columbia (DC), representing an increase of 1,295 cases (16%) as compared with 2022. The rate in 2023 (2.9 per 100,000 persons) also increased compared with that in 2022 (2.5). Forty states and DC reported increases in 2023 in both case counts and rates. National case counts increased among all age groups and among both U.S.-born and non-U.S.-born persons. Although TB incidence in the United States is among the lowest in the world and most U.S. residents are at minimal risk, TB continues to cause substantial global morbidity and mortality. This postpandemic increase in U.S. cases highlights the importance of continuing to engage communities with higher TB rates and their medical providers in TB elimination efforts and strengthening the capacity in public health programs to carry out critical disease control and prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.